Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10326694" target="_blank" >RIV/00179906:_____/16:10326694 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/16:10326694

Result on the web

<a href="http://dx.doi.org/10.2217/fon-2016-0137" target="_blank" >http://dx.doi.org/10.2217/fon-2016-0137</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/fon-2016-0137" target="_blank" >10.2217/fon-2016-0137</a>

Result language

angličtina

Original language name

Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma

Original language description

We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m(2) iv. on days 1, 8 and 15, combined with rituximab 375 mg/m(2) iv. on day 1, up to six cycles. Pixantrone has a conditional European marketing approval for monotherapy in adults with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of combining pixantrone with rituximab and completes postauthorization measures. Trial registration number: NCT01321541.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Future Oncology

ISSN

1479-6694

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

15

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

1759-1768

UT code for WoS article

000380370500005

EID of the result in the Scopus database

2-s2.0-84979780479